Kale, B., Grajales-Cruz, A., Blue, B., Avila, G. D., Scheiber-Camoretti, D., Silva, A. S., DeAvila, D., Matte, K. H., Oswald, L., Peres, L., Gonzalez, R., Liu, H., Shain, K., Baz, R., Nishihori, T., Alsina, M., Freeman, C. L., Locke, F., Perna, F., Puglianini, O. A. C., Hansen, D. (2025). ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.. Blood. https://doi.org/10.1182/blood-2025-5846